DRUG INDUCED LUNG DISEASES

Similar documents
CHAPTER II DRUG INDUCED PULMONARY DISEASES. BY J. jayasutha lecturer department of pharmacy practice Srm college of pharmacy SRM UNIVERSITY

ISPUB.COM. How Drugs Affect The Lungs. S Kumar, S Mehra BACKGROUND AGE RACE LIMITED KNOWLEDGE SEX RISK FACTORS FREQUENCY

Radiological Imaging of Drug-Induced Pulmonary Lesions

DOWNLOAD PDF DRUG-INDUCED LUNG DISEASES AND RADIATION PNEUMONITIS

Pulmonary Test Brenda Shinar

Systemic lupus erythematosus (SLE): Pleuropulmonary Manifestations

Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines

INTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf

Imaging Cancer Treatment Complications in the Chest

Acute Respiratory Distress Syndrome (ARDS) An Update

Nitrofurantoin-Induced Lung Toxicity

Resident Case Review CHEST. Daria Manos CAR 2016

4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs

INTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018

The Respiratory System

SESSION IV: MECHANISMS OF HUMAN DISEASE: LABORATORY SESSIONS PULMONARY PATHOLOGY I. December 5, 2012

Nitrofurantoin Pulmonary Toxicity: A Brief Review

Chapter 10 Respiratory System J00-J99. Presented by: Jesicca Andrews

New lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma

11/19/2012. The spectrum of pulmonary diseases in HIV-infected persons is broad.

Vasculitis local: systemic

Replacement of air with fluid, inflammatory. cells or cellular debris. Parenchymal, Interstitial (Restrictive) and Vascular Diseases.

PFT Interpretation and Reference Values

SCLERODERMA LUNG DISEASE: WHAT THE PATIENT SHOULD KNOW

Management of drug-induced interstitial lung disease Amitava Ganguli BSc, MRCP and Munir Pirmohamed PhD, FRCP

Pulmonary veno-occlusive disease

Lines and crackles. Making sense of ILD

Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)

HYPERSENSITIVITY PNEUMONITIS

Restrictive Pulmonary Diseases

Case 1. A 35-year-old male presented with fever, cough, and purulent sputum for one week. This was his CXR (Fig. 1.1). What is the diagnosis?

Case 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule

Vascular Lung Diseases

Interstitial Lung Diseases(ILD) By : Dr. Shaher M. Samrah Done by : Ibrahim M. sun

Pulmonary Pearls. Medical Pearls. Case 1: Case 1 (cont.): Case 1: What is the Most Likely Diagnosis? Case 1 (cont.):

Anatomy. The respiratory system starts from the nose, mouth, larynx, trachea, and the two lungs.

Pulmonary Complications of Antineoplastic Agents : Era of Targeted Therapy

Pathology of Pneumonia

PULMONARY MEDICINE BOARD REVIEW. Financial Conflicts of Interest. Question #1: Question #1 (Cont.): None. Christopher H. Fanta, M.D.

Respiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician

Radiation Pneumonitis Joseph Junewick, MD FACR

Pulmonary Function Testing The Basics of Interpretation

Case Report Acute Low-Dose Hydralazine-Induced Lupus Pneumonitis

VASCULITIC SYNDROMES. Howard L. Feinberg, D.O., F.A.C.O.I., F.A.C.R. OPSC 2018

Lung diseases of Vascular Origin. By: Shefaa Qa qqa

CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)

ISPUB.COM. Drug induced pulmonary diseases. S Verma, V Mahajan INTRODUCTION ETIOPATHOGENESIS EPIDEMIOLOGY

Chronic Lung Disease in vertically HIV infected children. Dr B O Hare Senior Lecturer in Paediatrics and Child Health, COM, Blantyre

Amiodarone Toxicities

Professor Rob Miller

PULMONARY HYPERTENSION

Liebow and Carrington's original classification of IIP

DISEASES OF THE RESPIRATORY SYSTEM 2017 DR HEYAM AWAD LECTURE 5: restrictive lung diseases, part 1: fibrosing lung diseases

Outline Definition of Terms: Lexicon. Traction Bronchiectasis

I have no relevant conflicts of interest to disclose

Respiratory Diseases and Disorders

The Pathologic Manifestations of Small Airway Disease. Samuel A. Yousem, MD. Small Airway Disease (SAD) SAD

Immune-mediated lung disease. Ian Sabroe

Vasculitis local: systemic

Case Study #2. Case Study #1 cont 9/28/2011. CAPA 2011 Christy Wilson PA C. LH is 78 yowf with PMHx of metz breast CA presents

V CHRONIC DIFFUSE INFILTRATIVE LUNG DISEASE

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

Unit II Problem 2 Pathology: Pneumonia

Pathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University

Radiologic findings of drug-induced lung disease

For more information about how to cite these materials visit

CALGARY ZONE PULMONARY REFERRAL QUICK REFERENCE

Pulmonary Pathophysiology

EOSINOPHLIC LUNG DISEASES

Tests Your Pulmonologist Might Order. Center For Cardiac Fitness Pulmonary Rehab Program The Miriam Hospital

Pulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?

The crazy-paving pattern: A radiological-pathological correlated and illustrated overview

CASE OF THE MONTH. Lung Disease in Rheumatoid Arthritis

Pulmonary Manifestations of Systemic Lupus Erythematosus 1

Hospital-acquired Pneumonia

Interstitial Lung Disease. SS Visser, Lung Unit, UP.

Financial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature

Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects

Basic mechanisms disturbing lung function and gas exchange

Parenchymal, Interstitial i (Restrictive) i and Vascular Diseases

CTD-related Lung Disease

Exacerbations. Ronald Dahl, Aarhus University Hospital, Denmark

Recognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis

Cardiovascular manifestations of HIV

Pulmonary Function Testing. Ramez Sunna MD, FCCP

4/16/2017. Learning Objectives. Interpretation of the Chest Radiograph. Components. Production of the Radiograph. Density & Appearance

HEMOPTYSIS. Prof. G. Zuliani

Pitfalls in Shortness of Breath

Atopic Pulmonary Disease: Findings on Thoracic Imaging

Imaging Small Airways Diseases: Not Just Air trapping. Eric J. Stern MD University of Washington

Atlas of the Vasculitic Syndromes

9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin

Case 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar

Case Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco

Lecture Notes. Chapter 3: Asthma

High Impact Rheumatology

Exam 2 Respiratory Disorders

Differential diagnosis

Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates

Transcription:

DRUG INDUCED LUNG DISEASES

CHEMOTHERAPEUTIC AGENTS 1. CYTOTOXIC ANTIBIOTICS 2. ALKYLATING AGENTS 3. ANTIMETABOLITES 4. BIOLOGIC RESPONSE MODIFIERS

CYTOTXIC ANTIBIOTICS BLEOMYCIN 1.CHRONIC PNEUMONITIS/ PULM FIBROSIS MOST COMMON SYNDROME RADIATION RECALL EFFECT RISK FACTORS: cumulative dose> 400u oxygen therapy therapeutic radiation renal insuff old age

2.HYPERSENSTIVITY TYPE LUNG DISEASES Dyspnea, cough, skin rash, eosinophilia may not occur with rechallange 3. CHEST PAIN SYNDROME Associated with iv infusion of the drug

MITOMYCIN C 1.CHRONIC PNEUMONITIS /PULMONARY FIBROSIS most common syndrome risk factors : oxygen therapy therapeutic radiation concurrent use of other cytotoxic drugs 2.ACUTE DYSPNEA/ BRONCHOSPASM NON CARDIOGENIC PULMONARY EDEMA pts receiving vinca alkaloids

3. HAEMOLYTIC UREMIC SYNDROME microangiopathic hemolytic anemia, thrombocytopenia, renal insuffieciency, non cardiogenic pumonary edema

ACTINOMYCIN D 1. EXACERBATION OF RADIATION INDUCED INJURY

ALKYLATING AGENTS BUSULFAN 1. CHRONIC PNEUMONITIS /PUMONARY FIBROSIS toxicity may occur after several years of treatment fibrosis may occur insidiously

CYCLOPHOSPHAMIDE 1. CHRONIC PNEUMONITIS /PULMONARY FIBROSIS risk factors: concurrent use of other cytotoxic drugs therapeutic radiation

ANTIMETABOLITES METHOTREXATE 1. CHRONIC PNEUMONITIS /PULMONARY FIBROSIS 2. HYPERSENSTIVITY TYPE 3. ACUTE CHEST PAIN SYNDROME often assoc with pleural effusions 4. NON CARDIOGENIC PULMONARY EDEMA assoc with intrathecal route

CYTOSINE ARABINOSIDE 1. NON CARDIOGENIC PULMONARY EDEMA FLUDARIBINE 1. HYPERSENSTIVITY RXN 2. INTERSTITIAL PNEUMONITIS

BIOLOGIC RESPONSE MODIFIERS ALLTRANS RETINOIC ACID 1. retinoic acid syndrome INTERLEUKIN 2 1. pleural effusions focal/ diffuse radiographic abnormalities risk factors: increasing cumulative dose admn of LAK cells IL 2 induced cardiac toxicity 2. NON CARDIOGENIC PULMONARY EDEMA

NON CHEMOTHERAPEUTIC AGENTS CARDIOVASCULAR DRUGS TOPICAL OPHTHALMIC AGENTS TOCOLYTICS CORTICOSTEROIDS ANTIBIOTICS ANTICONVULSANTS SALICYLATE GOLD & PENCILLAMINE ILLICIT DRUG USAGE

CARDIOVASCULAR DRUGS AMIODARONE incidence of pulmonary toxicity 5% 1. alveolitis/ / fibrosis sndrome a) chronic 2/3 rd cases b) subacute fever, chest pain, alveolar/mixed infiltrates leucocytosis,, raised ESR 2. NON CARDIOGENIC PULMONARY EDEMA

Daily dose < 400mg is assoc with lower risk PATHOLOGY accumulation of foamy macrophages acute intraalveolar h age type 2 cell proliferation Hyaline membrane formation on Electron m scopy cytoplasm of foamy macrophages has lamellar inclusions containing indigested phospholipids

PROCAINAMIDE DRUG INDUCED SLE ANA +ve+ ve, antihistone Ab Slow acetylators develop ANA & clinical SLE rapidly common symptoms: arthralgias,, fever Pleural effusions & pleuritic chest pain (MC pulmonary symptoms) Parenchymal infiltrates

ADENOSINE MC pulmonary side effect is acute dyspnea during infusion Acute bronhcospasm in asthma & COPD pts

ACE INHIBITORS chronic nonproductive cough 5-15% 5 angioneurotic edema BETA BLOCKERS pulmonary fibrosis drug induced SLE dose dependent decrease in FEV1

TOPICAL OPTHALMIC AGENTS Significant decrease in FEV1 in asymptomatic Acute bronchospasm Non specific agents timolol

TOCOLYTIC AGENTS ACUTE PULMONARY EDEMA BRONCHOSPASM METABOLIC ACIDOSIS AND DYSPNEA

CORTICOSTEROIDS LONE COUGH MEDIASTINAL FATTY DEPOSITS (LIPOMATOSIS) THROMBOEMBOLIC DISEASE OPPORTUNISTIC INFECTIONS

ANTIBIOTICS HYPERSENSTIVITY RXN PIE syndrome - beta lactams,, sulfa drugs MC is loeffler s syndrome c/f- dyspnea cough fever peripheral blood eosinophilia of acute onset spontaneous resolution on drug withdrawal

NITROFURANTOIN ACUTE CHRONIC Onset <1 mth after 1 st elderly pts undergoing Dose; recurs with challenge chronic oral therapy fever, dyspnea, cough, cough, dyspnea, Maculopapular rash cyanosis, fatigue Mixed infiltrates interstitial infiltrates PFT-restrictive defect with prognosis worse Decrease DLCO

INH INDUCED SLE fever anemia rash arthralgias Pleural effusions & pleuritic chest pain (MC pulmonary symptoms) ANA+ve,, anti histone Ab

ANTIBIOTIC ASSOCIATED ALVEOLAR HYPOVENTILATION AND HYPERCARBIC RESP FAILURE AMINOGLYCOSIDES ( MC DRUGS) seen in cases of: post operative pts. myasthenia like syndromes unrecognized myasthenia gravis

ANTICONVULSANTS DIPHENYLHYDANTOIN 1. asymptomatic physiological abnormalities 2. hypersensitivity syndrome 3. lymphocytic interstitial pneumonitis 4. pseudolymphoma syndrome

SALICYLATES ASPIRIN INDUCED ASTHMA aspirin sensitivity seen in 5% asthmatics SAMPTER S S TRIAD- nasal polyposis,, chronic sinusitis, asthma SALICYLATE INDUCED PULM EDEMA 10-15% 15% of salicylate overdosing metab acidosis with resp alkalosis Significant proteinuria CXRAY- perihilar alveolar infiltrates with pleural effusion and cardiomegaly

GOLD seen in treatment of osteoarthritis, pemphigus Assoc with HLAB 40 & HLAB 35 typically interstitial pneumonitis c/f cough fever skin rash peripheral blood eosinophilia Lung biopsy- alveolar septal thickening interstitial fibrosis mononuclear cell infiltrate

PENCILLAMINE 1. Interstitial Lung Diseases 2. Bronchiolitis Obliterans 3. Pulmonary Renal Syndrome

COMPLICATIONS OF ILLICIT DRUG USE Alveolar hypoventilation & hypercarbic resp failure Endocarditis, septic emboli HIV assoc infections Tuberculosis Complications of central cannulation pneumothorax intravascular infections arterial aneurysms and dissections

Foreign body granulomatosis Opiate induced pulmonary edema Cocaine crack lung bronchospasm pneumothorax, pneumomediastinum airway burns non cardiac pulmonary edema pulmonary infiltrates with eosinophilia acute alveolar h age syndrome

TREATMENT DRUG CESSATION CORTICOSTEROIDS

EMPERICAL GUIDELINES FOR USE STEROIDS IN DIRD s Pattern of Involvement Indication for Steroids Duration of Treatment Level of Scientific Evidence Laryngeal edema Y Days 1 Sudden severe asthma Y Weeks 1 Worsening of asthma Y As needed 2 Bronchiolitis obliterans Y Months 2 Classic interstitial pneumonia (NSIP) Pulmonary infiltrates and eosinophilia Y A few weeks or months 2 Y A few weeks or months 2, 3 Amiodarone lung Y 6 to 18 mo 3 Organizing pneumonia Y A few months 3 Desquamative interstitial pneumonia Y A few months? 1 Pulmonary fibrosis Y Months 2, 3 Lipoid pneumonia N 1 Pulmonary edema? Pulmonary hypertension N Alveolar hemorrhage Y? Months 2 Hemolytic-uremic syndrome Y?? 2 Veno-occlusive disease N

All the best..